• Japanese
  • Korean
  • Chinese
Cover Image

Nanotechnology for Drug Delivery: Global Market for Nanocarriers

Abstract

Nanocarriers will account for 40% of a $136 billion nanotechnology-enabled drug delivery market by 2021. We forecast the total market size in 2021 to be US$136 billion, with a 60/40 split between nanocrystals and nanocarriers respectively, although developing new targeted delivery mechanisms may allow more value to be created for companies and entrepreneurs.

Of the 10 nanocarrier technologies studied, liposomes and gold nanocarriers account for 45% of the total addressable market. Liposomes will offer the largest addressable market ($15 billion) in 2021 while gold nanocarriers will see the highest compound annual growth rate (CAGR) - 53.8% - in the next decade.

Drugs are loaded into nanocarriers (also called nanoshells or nanoparticles, between 1 and 100 nm), then transported through the body to the target site. This kind of targeted drug delivery for the treatment of cancers is one of the most anticipated and discussed benefits of nanotechnology-enabled medicine as it offers a level of accuracy in delivering drugs that far surpasses present methods. Typically over 90% of a drug is wasted in the body, which leads to unwanted side effects. Modern chemotherapy bombards patients with drugs in the hope that tumorous cells will be destroyed. The lack of specificity of current drug delivery techniques mean patients' healthy cells are destroyed indiscriminately along with cancer cells.

Using nanotechnology to combat cancer is not new. Abraxane, the first nanoparticulate drug delivery product for the treatment of breast cancer, launched six years ago. There are now hundreds of new nanotech-based treatments under development, ranging from reformulation of existing drugs to enhance their efficacy to radical new "magic bullet" therapies.

The healthcare market is changing. We are seeing a paradigm shift away from blockbusters and a 'one-size fits all' approach to a more personalised medicine based on an individual's unique genome and immune response. The more scientists learn about the molecular causes for disease the more targeted and effective nanotechnology-enabled drug delivery therapies will become.

Table of Contents

TABLE OF EXHIBITS

EXECUTIVE SUMMARY

CHAPTER 1 - INTRODUCTION

  • REPORT SCOPE
  • METHODOLOGY
    • Procurement
    • Calculation of CAGR
  • THE NANOSCALE
    • Two biological examples that illustrate nanoscale:

CHAPTER 2 - NANOTECHNOLOGY IN MEDICINE AND BIOMEDICINE

  • OVERVIEW OF NANOTECHNOLOGY IN MEDICINE AND BIOMEDICINE
    • Why is Nanotechnology A Critical Application for Medicine and Biomedicine?
    • Why Nanotechnology Is Needed for Medicine and Biomedicine
  • WHAT ARE THE KEY DRIVERS FOR ADOPTION OF NANOTECHNOLOGY IN MEDICINE AND BIOMEDICINE?
    • The Aim Of Drug Targeting
    • Rapid Market Growth
    • Market Drivers For Enhanced Drug Delivery
    • Increasing Proportion of The Ageing Population
    • Demand For More Affordable Health Care
    • Public Health - Ending disease
    • Demand for More Innovation
    • Social responsibility
  • THE KEY APPLICATIONS OF NANOTECHNOLOGY IN MEDICINE AND BIOMEDICINE
    • How Nanotechnology Can Benefit Drug Delivery
    • Nanotechnology in Medical and Biomedical Diagnostics
    • Nanotechnology in Regenerative Medicine and Tissue Engineering
    • Other Applications For Nanomaterials In The Medical And Pharmaceutical Sector
  • PROMISING EXAMPLES OF NANOTECHNOLOGY ENABLED DRUG DELIVERY
    • Case Study 1 - Magnetic Field Acts as "Remote Control" to Deliver Nanomedicine
    • Case Study 2 - Adaptive Micro and Nanoparticles: Temporal Control Over Carrier Properties to Facilitate Drug Delivery
    • Case Study 3 - Fabrication of a Nanocarrier System Through Self-Assembly of Plasma Protein And Its Tumour Targeting
    • Case Study 4 - IBM And The Institute of Bioengineering And Nanotechnology Find Breakthrough For MRSA

CHAPTER 3 - RISK & REGULATION 43

  • THREE KEY BARRIERS TO THE ADOPTION OF NANOTECHNOLOGY IN MEDICINE AND BIOMEDICINE
    • Nanotoxicity Nanopollution and Nanosafety
    • Ethical Considerations Of Nanotherapies
    • Delayed Nanoregulation
  • FIVE CURRENT & FUTURE CHALLENGES IN THE ADOPTION OF NANOTECHNOLOGY IN MEDICINE AND BIOMEDICINE
    • Current & Future Challenges of Nanosafety And Risk Management
    • Current & Future Challenges of Nanoregulation
    • Current & Future Challenges for the Nanomedicine Industry
    • Current & Future Challenges of Sustained Innovation
    • Current & Future Challenges of Cooperation

CHAPTER 4 - MARKET FOR NANOCARRIERS

  • GLOBAL MARKET ANALYSIS: 2000-2010 (WITHOUT SEGMENTATION)
  • GLOBAL MARKET FORECAST: 2011-2021 (WITHOUT SEGMENTATION)
  • DISCUSSION OF NANOPARTICLES & NANOCARRIERS
    • Overview of The Key Nanotechnologies Used in Drug Delivery Sorted by Applications
    • Nanopharmaceuticals
    • Nanotechnology In Drug Delivery
    • Nanobiotechnology In Drug Delivery
    • Analytical Techniques For Nanoparticle Drug Delivery
    • Properties
    • Production of Nanoparticles
    • Measuring Dispersion of Nanoparticles
    • Characterisation of Carrier Systems
    • Nanocarriers
    • Classification of Nanocarriers
    • Multifunctional Nanocarriers - Drug Delivery And Medical / Biomedical Diagnostics
    • Nanocarriers as Drug Carriers
    • What Can Nanoparticles do in Drug Delivery?
    • Polymer-Based Nanocarriers (Polymeric Nanoparticles)
    • Lipid-Based Nanocarriers
    • Organic Nanocarriers
    • Inorganic Nanocarriers
    • Disadvantages Associated With Nanocarriers
    • The Most Relevant Technologies in The Key Area of Nanotechnology in Drug Delivery
    • Stage of Development of Key Nanotechnologies Used in Drug Delivery
    • Clinically Approved Nanocarrier-Based Drug Formulations With Presence on The Market
    • The First Nanoparticle Drug Delivery System Reaches The Market 81
    • Present And Future Applications
  • TECHNOLOGY ADOPTION ROADMAP
    • Projected Product Pipeline For Nanocarrier-Based Drug Formulations In Drug Delivery Market
    • Available Applications Of Nanoparticles In Drug Delivery
    • Semapimod®(cytokine, pharmasciences)
    • Paxceed™
    • Theralux™
    • NucrystR
    • iSPERSE™
  • ANALYSIS OF TAM FOR NANOCARRIERS: 2000-2010
  • TAM FORECAST FOR NANOCARRIERS: 2011-2021

APPENDIX

  • PUBLISHING ACTIVITY BY ORGANIZATION (2000-2010)

Table of Exhibits

  • Exhibit 1.1
  • Formula for the calculation of the Compound Annual Growth Rate (CAGR), (top).
  • Formula for the calculation of the Compound Annual Growth Rate (CAGR) in this report, for the 2011-2021 period, (bottom) [2].
  • Exhibit 1.2
  • Formula for the verification of the calculated values of the Compound Annual Growth Rate (CAGR), (top).
  • Formula for the verification of the calculated values of the Compound Annual Growth Rate (CAGR) in this report, for the 2011-2021 period, (bottom) [2].
  • Exhibit 1.3
  • Nanometers in a meter (top). Meters in a nanometer (bottom).
  • Exhibit 2.1
  • Illustration of the fact that the periodic table of elements, as we know it (at meter scale) governed by classic Newtonian laws of physics. However, when perceived at nanoscale, those elements are governed by the laws of quantum physics.
  • Exhibit 2.2
  • Proportion of the population aged over 65 and over 80 [7].
  • Exhibit 2.3
  • Illustration of a diagram of each property of nanocarriers (size, shape, surface chemistry and mechanical properties) and their parameters subjected to optimization in order to improve their efficiency [10].
  • Exhibit 3.1
  • Specified expected barriers in the development of particular types of nanoparticles (Courtesy of CienNanoroadmap Synthesis Report), [6].
  • Exhibit 3.2
  • Illustration of the measures adoption roadmap to combat/attenuate the key barriers to the adoption of nanotechnology in medicine and biomedicine (Source: Cientifica, Ltd.).
  • Exhibit 3.3
  • Table representing the Total Addressable Market, TAM (2000-2010), for nanotechnology in drug delivery, without segmentation, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 3.4
  • Line chart representing Total Addressable Market, TAM (2000-2010), for nanotechnology in drug delivery, without segmentation, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 3.5
  • Bar chart representing Total Addressable Market, TAM (2000-2010), for nanotechnology in drug delivery, without segmentation, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 3.6
  • Table representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, without segmentation, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 3.7
  • Line chart representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, without segmentation, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 3.8
  • Bar chart representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, without segmentation, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.1
  • Typical Image of Colloidal Gold Nanoparticles [1].
  • Exhibit 4.2
  • Examples of nanocarriers used for targeting cancer. (A) A whole range of delivery agents are possible but the main components typically include a nanocarrier, a targeting moiety conjugated to the nanocarrier and a cargo (such as the desired chemotherapeutic drugs); (B) Schematic diagram of the drug conjugation and entrapment processes. The chemotherapeutics could be bound to the nanocarrier, as in the use of polymer - drug conjugates, dendrimers and some particulate carriers or they could be entrapped inside the nanocarrier [3].
  • Exhibit 4.3
  • Schematic representation of different mechanisms of drug delivery to tumours using nanocarriers. Polymeric nanoparticles are shown as representative nanocarriers (circles). Passive tissue targeting is achieved by extravasation of nanoparticles through increased permeability of the tumour vasculature and ineffective lymphatic drainage (EPR effect). Active cellular targeting (inset) can be achieved by functionalizing the surface of nanocarriers with ligands that induce cell-specific recognition and binding. The nanocarriers can (a) release their contents in close proximity to the target tumour cells; (b) attach to the membrane of the tumour cell and play the role of an extracellular sustained-release drug depot; or (c) internalize into the tumour cell [3].
  • Exhibit 4.5
  • Representative examples of clinically approved nanocarrier-based drug formulations with presence on the market [4].
  • Exhibit 4.6
  • Some examples of nano-based platforms and their current stage of development for use in cancer therapy [3].
  • Exhibit 4.26
  • Table representing the Total Addressable Market, TAM (2000-2010), for nanotechnology in drug delivery, all most relevant key technologies, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.27
  • 3-D pie chart representing the Total Addressable Market, TAM in 2010, for nanotechnology in drug delivery, all key technologies studied, source: Cientifica (all figures in percentage).
  • Exhibit 4.28
  • Horizontal bar graph representing the Total Addressable Market, TAM in 2010, for nanotechnology in drug delivery, all key technologies studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.29
  • Line chart representing the Total Addressable Market, TAM (2000-2010), for nanotechnology in drug delivery, all key technologies studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.30
  • 3-D stacked vertical bar graph representing the Total Addressable Market, TAM (2000-2010) , for nanotechnology in drug delivery, all key technologies studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.31
  • 3-D stacked area chart representing the Total Addressable Market, TAM (2000-2010) , for nanotechnology in drug delivery, all key technologies studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.32
  • 3-D pie chart representing the Total Addressable Market, TAM in 2010, for nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica (all figures in percentage).
  • Exhibit 4.33
  • Horizontal bar graph representing the Total Addressable Market, TAM in 2010, for nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.34
  • Line chart representing the Total Addressable Market, TAM (2000-2010), for nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.35
  • 3-D stacked vertical bar graph representing the Total Addressable Market, TAM (2000-2010) , for nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.36
  • 3-D stacked area chart representing the Total Addressable Market, TAM (2000-2010) , for nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.45
  • In vivo effects of nanocrystals-based drug formulations [6].
  • Exhibit 4.67
  • Table representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, all key technologies, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.68
  • 3-D pie chart representing the Total Addressable Market, TAM forecast in 2021, for nanotechnology in drug delivery, all key technologies studied, source: Cientifica (all figures in percentage).
  • Exhibit 4.69
  • Horizontal bar graph representing the Total Addressable Market, TAM forecast in 2021, for nanotechnology in drug delivery, all key technologies studied, source: Cientifica (all figures in percentage).
  • Exhibit 4.70
  • Line chart representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, all key technologies studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.71
  • 3-D stacked vertical bar graph representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, all key technologies studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.72
  • 3-D stacked area chart representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, all key technologies studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.73
  • 3-D pie chart representing the Total Addressable Market, TAM forecast in 2021, for nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica (all figures in percentage).
  • Exhibit 4.74
  • Horizontal bar graph representing the Total Addressable Market, TAM forecast in 2021, for nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.75
  • Line chart representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.76
  • 3-D stacked vertical bar graph representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.77
  • 3-D stacked area chart representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.78
  • 3-D pie chart representing the Total Addressable Market, TAM forecast in 2021, for nanotechnology in drug delivery, nanocarriers versus drug nanocrystals, source: Cientifica (all figures in percentage).

Appendix

  • Exhibit A.1
  • Table of the top 20 organizations showing the highest publishing activity in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. World Region: North America; country: USA.
  • Organizations are ordered first by descending order of total articles published and then ordered alphabetically (increasing order), if applicable.
  • Exhibit A.2
  • Table of the top 20 organizations showing the highest publishing activity in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. World Region: European Union; country: Germany.
  • Organizations are ordered first by descending order of total articles published and then ordered alphabetically (increasing order), if applicable.
  • Exhibit A.3
  • Table of the top 20 organizations showing the highest publishing activity in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. World Region: European Union; country: France.
  • Organizations are ordered first by descending order of total articles published and then ordered alphabetically (increasing order), if applicable.
  • Exhibit A.4
  • Table of the top 20 organizations showing the highest publishing activity in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. World Region: European Union; country: UK.
  • Organizations are ordered first by descending order of total articles published and then ordered alphabetically (increasing order), if applicable.
  • Exhibit A.5
  • Table of publishing activity in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. Country: Russian Federation.
  • Organizations are ordered alphabetically (increasing order).
  • Exhibit A.6
  • Table of the top 20 organizations showing the highest publishing activity in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. World Region: Asia; country: India.
  • Organizations are ordered first by descending order of total articles published and then ordered alphabetically (increasing order), if applicable.
  • Exhibit A.7
  • Table of the top 20 organizations showing the highest publishing activity in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. World Region: Asia; country: India.
  • Organizations are ordered first by descending order of total articles published and then ordered alphabetically increasing order), if applicable.
  • Exhibit A.8
  • Table of the top 20 organizations showing the highest publishing activity in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. World Region: Asia; country: Japan.
  • Organizations are ordered first by descending order of total articles published and then ordered alphabetically (increasing order), if applicable.
  • Exhibit A.9
  • Table of the top 20 organizations showing the highest publishing activity in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. World Region: Asia; country: P R China.
  • Organizations are ordered first by descending order of total articles published and then ordered alphabetically (increasing order), if applicable.
  • Exhibit A.10
  • Table of the top 20 organizations showing the highest publishing activity in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. World Region: Asia; country: South Korea (Republic of Korea).
  • Organizations are ordered first by descending order of total articles published and then ordered alphabetically (increasing order), if applicable.
  • Exhibit A.11
  • Table of publishing activity in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. Asia; country: Taiwan.
  • Organizations are ordered first by descending order of total articles published and then ordered alphabetically (increasing order), if applicable.
Show More
Pricing